1-[3-(2-Methylpropyl)pyrrolidin-1-yl]prop-2-en-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-[3-(2-Methylpropyl)pyrrolidin-1-yl]prop-2-en-1-one
• 英文别名: 1-[3-(2-methylpropyl)pyrrolidin-1-yl]prop-2-en-1-one
• 化学式: C₁₁H₁₉NO
• 分子量: 181.27
• InChiKey: ONLPYFVQWIVJOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Thiazolyl-containing compounds for treating proliferative diseases
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10464949B2

  公开（公告）日：2019-11-05

  The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma (e.g., Waldenström's macroglobulinemia)) and in inducing apoptosis in a cell (e.g., malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了式(I)、(II)或(III)的含噻唑化合物。本文所述化合物可抑制蛋白激酶（如 Src 家族激酶（如造血细胞激酶 (HCK)）、布鲁顿酪氨酸激酶 (BTK)），可用于治疗和/或预防增殖性疾病（如、骨髓增生异常、白血病、淋巴瘤（如瓦尔登斯特伦巨球蛋白血症））和诱导细胞（如恶性血细胞）凋亡。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。
• Compounds and methods for modulating bruton's tyrosine kinase
  申请人：CORVUS PHARMACEUTICALS, INC.

  公开号：US10870652B2

  公开（公告）日：2020-12-22

  Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.

  本文特别提供了调节布鲁顿酪氨酸激酶的化合物和方法。
• Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
  申请人：BEIGENE SWITZERLAND GMBH

  公开号：US11142528B2

  公开（公告）日：2021-10-12

  The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

  本发明是式(I)的融合杂环化合物及其盐类、组合物和使用方法。特别是，本文公开的某些融合杂环化合物可用于抑制蛋白激酶，包括布鲁顿酪氨酸激酶（Btk），以及治疗由其介导的疾病。
• AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：ETERNITY BIOSCIENCE INC.

  公开号：US20170152264A1

  公开（公告）日：2017-06-01

  The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
• THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170233411A1

  公开（公告）日：2017-08-17

  The present disclosure provides thiazolyl-containing compounds of Formula (I), (II), or (III). The compounds described herein may be able to inhibit protein kinases (e.g., Src family kinases (e.g., hemopoietic cell kinase (HCK)), Bruton's tyrosine kinase (BTK)) and may be useful in treating and/or preventing proliferative diseases (e.g., myelodysplasia, leukemia, lymphoma (e.g., Waldenstrom's macroglobulinemia)) and in inducing apoptosis in a cell (e.g., malignant blood cell). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.